Academic Pharmacy Now: 2016 Issue 2

Academic Pharmacy NOW

The News Magazine of the American Association of Colleges of Pharmacy

Volume 9 2016 Issue 2

Not Blowing Smoke Academic pharmacy aims to reduce tobacco use to ashes. 12

Also in this issue: Decades-long research on Sickle Cell Disease pays off 5 A glucose monitor small in size, but large in impact 9

who we are @AACPharmacy

Academic Pharmacy The News Magazine of the American Association of Colleges of Pharmacy

American Association of Colleges of Pharmacy 1727 King Street, Floor 2 Alexandria, VA 22314 p: 703-739-2330 P f: 703-836-8982

www.aacp.org

Founded in 1900, the American Association of Colleges of Pharmacy is the national organization representing the interests of pharmacy education. AACP comprises all accredited colleges and schools of pharmacy, including more than 6,600 faculty, approximately 63,800 students enrolled in professional programs and 4,800 individuals pursuing graduate study.

Letters to the Editor

NOW

CEO & Publisher

Lucinda L. Maine

Editorial Director

Lynette R. Bradley-Baker

Editor

Maureen Thielemans

mthielemans@aacp.org

Editorial Assistant

Kyle R. Bagin

We welcome your comments.

Please submit all letters to the editor to communications@aacp.org.

About Academic Pharmacy Now Academic Pharmacy Now highlights the work of AACP member pharmacy schools and faculty. The magazine is published as a membership service.

Subscriptions To subscribe, visit http://www.aacp.org/news/ shopaacp/Pages/publications.aspx.

Change of Address For address changes, contact Terry J. Ryan, Associate Director of Membership Development, at tryan@aacp.org.

Advertising For advertising rates, please visit http://www.aacp.org/news/academic pharmnow/pages/advertisingwithaacp.aspx. Š2016 by the American Association of Colleges of Pharmacy. All rights reserved. Content may not be reprinted without prior written permission.

2

Academic Pharmacy NOW  2016 Issue 2

kbagin@aacp.org

Art Director

Tricia Gordon

tgordon@aacp.org

Web Designer

Sean Clark

sclark@aacp.org

Freelance Writer

Athena Ponushis

Senior Advisor, Outreach and Communications

Stephanie Saunders Fouch sfouch@aacp.org

Volume 9 2016 Issue 2

@AACPharmacy a look inside

campus connection

5

7

All in Good Time Researchers at VCU have worked long and hard to translate their discoveries related to sickle cell disease, and hopefully have a new therapeutic intervention to show for it.

Building Interprofessional Momentum A forward-thinking endeavor plans to transform clinical practices and educational programs through interprofessional faculty teams.

community impact

9

10

12

Small in Size, Large in Impact A new implantable glucose monitor from a team of researchers at the University of Connecticut is about to take a big journey.

Not Blowing Smoke Academic pharmacy aims to reduce tobacco use to ashes.

A Pathway to a Possible HIV Cure UNMC pharmacy dean is part of international research team that looked at HIV drug delivery.

@AACPharmacy

21

Connecting Our Knowledge Assets

22

AACP Interim Meeting: Innovation and Effective Leadership

Academic Pharmacy NOW  2016 Issue 2

3

community note publisher’s impact

Dear Colleagues: This issue of Academic Pharmacy Now will hit your inbox in the last frenetic days of the 2015-16 academic year.

Hooding ceremonies, honor banquets, commencement ceremonies and many touching moments will crowd your days. I hope as things quiet down a bit you’ll find a few moments to flip through this issue of our magazine.

Innovation, transformation, change—these are the words I hear most often these days no matter what the context or group I am part of. As noted in the brief recap of the Interim Meeting, these were the primary themes of our excellent presenters in Tampa in February.

Innovation is also the focus of the Opening General Session keynote in Anaheim in July. In addition, you’ll hear more about transformational change as Bob Blouin and Todd Sorensen, the Council of Deans and Council of Faculties chairs respectively, share how their accelerating change task force has outlined a plan of action for how AACP can partner with our members in rapid cycle change projects to create innovation and transformation of both education and practice.

egates sessions. We were challenged by last year’s strategic planning committee to produce a bold and visionary plan and we hope that the priorities outlined in the new plan meet that mark. Clearly working with you to fill the pipeline with the right number and quality of learners is Job #1. To do that we need to paint a fresh picture of what pharmacy in the 21st century is about. Too big a job for AACP and the Academy alone, we seek strategic partners across the profession to embark on this journey. And we don’t overlook the strategically important mission of strong research and graduate education.

Join us for one of the two May webinars to discuss the plan and all the business coming to the House in July.

The dates, times and call information will be included in the House of Delegates Bulletin sent to all delegates in early May. They will also be communicated in the next several E-Lert announcements.

In May, AACP will be releasing our draft 2016-19 strategic plan for review by the delegates and other members and for discussion leading up to the 2016 House of Del-

Sincerely,

Lucinda L. Maine, Ph.D., R.Ph. CEO and Publisher

www.ajpe.org

Help Shape the Future of Pharmacy Become a Reviewer for AJPE A complete list of reviewer instructions can be found on AJPE’s Web site at www.ajpe.org.

You can sign up at any time by contacting Amanda Thomason at athomason@ajpe.org or 703-739-2330 ext. 1049.

4

Academic Pharmacy NOW  2016 Issue 2

Spread the Word Tell respected colleagues to review for AJPE, the premier scholarly journal of academic pharmacy. You will be sharing the opportunity to advance professionally while keeping the Journal fresh and relevant with a diversity of ideas from the Academy.

campus connection

All in Good Time

Researchers at VCU have worked long and hard to translate their discoveries related to sickle cell disease, and hopefully have a new therapeutic intervention to show for it.

By Cynthia McMullen Three decades can be a blink of an eye in the research community. That’s especially true when the drugs a team is working on hold promise for a major public health concern such as sickle cell disease (SCD).

Nearly three decades—to be more precise, 28 years—is how long researchers at Virginia Commonwealth University School of Pharmacy have been working to discover a treatment for this painful, sometimes life-threatening genetic blood disorder. It affects about 100,000 Americans, and African-Americans in particular.

SCD can lead to chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, chronic organ damage, morbidity and mortality. VCU School of Pharmacy’s search for effective treatment of this debilitating disease began when Dr. Donald Abraham came on board in 1988 as chairman of the Department of Medicinal Chemistry.

Abraham, whose interest in sickle cell disease dates back to the mid-‘70s, retired about nine years ago…but not before he and his team had made several discoveries in SCD therapeutics. One molecule, vanillin, was promising but

metabolized too quickly in the body.

That’s what led the team to 5-HMF, a byproduct of browning sugar that appeared to be effective in managing SCD by targeting the abnormal hemoglobin that causes it.

Since Abraham’s retirement, Dr. Martin Safo has led the ongoing SCD drug discovery effort within the Institute for Structural Biology, Drug Discovery and Development. The institute, founded

by Abraham, is an interprofessional research center whose investigators are affiliated primarily with the School of Pharmacy or the School of Medicine.

Dr. Martin Safo conducted research on sickle cell disease as a VCU School of Pharmacy postdoc in 1991. He has been on faculty since 1998.

Photo credit: Brian Canaday

Academic Pharmacy NOW  2016 Issue 2

5

campus connection

A Breakthrough Agent Safo, an associate professor of medicinal chemistry, explains that with SCD, a mutation in the beta-globin chain of hemoglobin causes the sickle hemoglobin to form insoluble polymers under hypoxia or when deoxygenated, resulting in sickling of red blood cells.

These deformed, rigid, crescent-shaped red blood cells, or sickle cells, cannot squeeze through small blood vessels, depriving organs of oxygen with concomitant anemia, organ damage and several other secondary pathophysiological events.

The only current FDA-approved treatment is hydroxyurea, an anticancer drug that, according to the National Center for Advancing Translational Sciences, is moderately effective and has undesirable side effects.

The modus operandi for School of Pharmacy researchers, says Safo, has been to use structure-based drug design—including X-ray crystallography, molecular molding, synthesis and biological evaluation—to aid in the search for hemoglobin allosteric effectors that prevent the hypoxia-induced polymerization of sickle hemoglobin to treat SCD.

In 2002, the team—Abraham, Safo and Richmond Danso-Danquah—disclosed the discovery of the antisickling agent 5-HMF to VCU Innovation Gateway.

Over the years, Innovation Gateway helped move the compound—eventually relabeled as Aes-103—to market by serving as a liaison to outside companies, facilitating commercialization and supporting research through collaborative agreements.

And in 2014, their research efforts inspired the university to present them with the VCU Innovation Gateway’s Billy R. Martin Award for Innovation.

Building a Better Compound Dr. Frank Macrina, VCU vice president for research and innovation, notes that NIH director Francis Collins has pointed to Aes-103 as a prime example of translational medicine where academic medical centers work with startup companies to research and develop life-changing drug therapies. Aes-103, in fact, is one of the first molecules to enter the NIH Therapeutics for Rare and Neglected Diseases program.

The NIH agreed to support Aes-103’s first three trials with a $5 million grant.

AesRx, a startup biopharmaceutical company, was developing Aes-103 when

both the company and the compound were acquired by Baxter International.

It was the first time a company had acquired a drug candidate developed in part by the TRND program.

Safo’s research in this area has generated more than $3 million in grants and royalties thus far. He continues with the assistance of colleagues such as Dr. Jurgen Venitz, professor of pharmaceutics, and Dr. Yan Zhang, associate professor of medicinal chemistry; graduate students and postdocs.

Phase I and phase II of the Aes-103 clinical trials now are complete. Early trials demonstrated that patients who took one dose experienced significantly less pain.

However, says Safo, Baxalta—the new name for Baxter International’s biopharmaceuticals business—has suspended studies with Aes-103 to start preclinical studies with a second-generation compound, TD-7, a derivative of the previously studied vanillin.

“TD-7 significantly improves on vanillin or 5-HMF antisickling effects with improved pharmacokinetic properties, both in vitro and in vivo,” he says. “In addition to preventing the hypoxiainduced polymerization of sickle hemoglobin as observed for vanillin or 5-HMF, TD-7 also directly destabilizes the sickle hemoglobin polymer, explaining its enhanced pharmacologic effect.”

The road from bench to bedside can be a long one, spanning decades. But where there’s research—and research funding—there’s hope. P Cynthia McMullen is Director of Public Relations and Communications at Virginia Commonwealth University School of Pharmacy.

Safo (right), pictured with Dr. Michael Rao, president of VCU, received a university award for sickle cell research.

6

Academic Pharmacy NOW  2016 Issue 2

Photo credit: VCU University Relations

campus connection

Building Interprofessional Momentum A forward-thinking endeavor plans to transform clinical practices and educational programs through interprofessional faculty teams.

By Athena Ponushis In order for interprofessional practice to be a reality, it cannot solely exist in the classroom, it has to happen in real-world settings. A new, national program—Professionals Accelerating Clinical and Educational Redesign (PACER)—looks to close that gap.

Nine institutions have been chosen to participate in the project. Interprofessional faculty teams will attend training sessions and work closely with expert coaches to elevate their interprofessional practice.

Here, Dr. Joseph Saseen, professor and vice chair of the Department of Clinical Pharmacy at the University of Colorado Skaggs School of Pharmacy, shines some light on the program, from its origin.

Q: What are the goals of the PACER project?

A: The goal is clinical transformation from the perspective of medical residency training. We want to allow sites that have medical residency programs to engage in educational and clinical transformation, to be full interprofessional practices. There’s definitely a focus on having more than just physicians’ perspectives in residency training, and to make it interprofessional and interdisciplinary as far as having pharmacy, nursing and other health disciplines involved, as appropriate.

Q: The PACER project looks to catalyze transformation and foster collaboration. What transformation are you envisioning?

A: I don’t think there’s going to be one definition because there are nine different practices that are part of this.

Each program is at a different level of interprofessional collaboration, and the changes should be meaningful and somewhat individualized. This is not about helping practices become interprofessional, it’s about getting the ones that are already on that road to achieving even higher accomplishments.

The idea of transformation is recognizing the importance of a multidisciplinary or interprofessional team working together, not only for the benefit of patients, but also determining how that impacts the training environment.

This stands in contrast to some other interprofessional efforts that we see in pharmacy, which often focus on the education perspective. We are trying to make clinical education at the medical resident level better.

Q: What is your role with this project and how did you become involved?

A: I am on the steering committee for the PACER project. One of my colleagues, Dr. Larry Green, professor of family medicine and Epperson

Dr. Joseph Saseen represents pharmacy education and clinical practice perspectives on the PACER project’s steering committee.

Zorn Chair for Innovation in Family Medicine and Primary Care, has been a physician in our department of family medicine for decades. As former chair of the department, he was one of the thought leaders of this PACER initiative and I’ve worked with him on many different endeavors, including within the medical residency program at the University of Colorado as part of the interdisciplinary team. Larry asked me to represent the pharmacy education and clinical practice perspectives. Subsequently, I should say, one of the sites that was selected is the program that I work for, though I had no part in compiling or evaluating that application.

Academic Pharmacy NOW  2016 Issue 2

7

campus connection

“The idea of transformation is recognizing the importance of a multidisciplinary or interprofessional team working together, not only for the benefit of patients, but also determining how that impacts the training environment.” ­— Dr. Joseph Saseen Q: Ultimately, the nine interprofessional teams will reach out into the community, collaborate with other primary care residencies, and then the PACER project intends to open three regional centers to expand the collaborative vision, is that right?

A: Yes, some of that is still in flux. How exactly that happens is still going to be determined based on how the groups work together, what their individual needs are, and how we can actually advance each program to a higher level.

Q: Where is each team located and what disciplines are represented on the teams?

A: They’re positioned all across the country and there’s a pharmacy component represented in just about every team, some to a greater extent than others. Other professions include nursing, medicine, behavioral science or behavioral health, and psychiatry. All sites are a little bit different from each other.

Q: Why is this project so critical to advancing patient care?

A: There is a disparity between how people are taught in a classroom and how it extrapolates into practice. Universities see the value in interprofessional education and we can push to have it implemented across universities,

schools of pharmacy, schools of medicine, nursing and so on. However, what happens after students leave the classroom? Students learn how to work with each other, how to talk with each other in the classroom, but when they visit practice sites they simply don’t always have the training environments universally where they see everybody working together. This can help address that gap. Interprofessional education was the first step, but maybe it should have started with interprofessional practice and worked backwards. P Athena Ponushis is a freelance writer based in Ft. Lauderdale, Florida.

The Nine PACER Teams 1. Eastern Virginia Medical School; Children’s Hospital of the King’s Daughters; Old Dominion University

6. UCSF Fresno Medical Education Program; Community Regional Medical Center

2. Mayo Clinic College of Medicine

7. University of Colorado School of Medicine, College of Nursing, Skaggs School of Pharmacy, and Physician Assistant Program

3. The North Shore-Long Island Jewish Health System (soon to be Northwell Health), Division of Internal Medicine, Department of Family Medicine, and Department of Pediatrics; Hofstra North Shore-LJI School of Graduate Nursing and Physician Assistant Studies; St. John’s College of Pharmacy and Health Sciences, Department of Clinical Pharmacy 4. Palmetto Health and the University of South Carolina 5. UC Davis School of Medicine and School of Nursing; University of California Health System; Sacramento County Primary Care Center; Transforming Education and Community Health (TEACH) Clinic

8

Academic Pharmacy NOW  2016 Issue 2

8. Western Michigan University Homer Stryker M.D. School of Medicine, Bronson School of Nursing, and Department of Psychology 9. Wright State University Boonshoft School of Medicine, College of Nursing and Health, and School of Professional Psychology; Cedarville University School of Pharmacy; Kettering College Physician Assistant Program

community impact

Small in Size, Large in Impact A new implantable glucose monitor from a team of researchers at the University of Connecticut is about to take a big journey.

Dr. Diane Burgess, Board of Trustees Distinguished Professor of Pharmaceutics at the University of Connecticut School of Pharmacy, along with colleagues from the School of Engineering and College of Liberal Arts and Sciences, is reaching new heights with a tiny glucose monitor the size of a grain of rice. The team’s work on this device to check blood sugar levels in diabetics has served as the basis of the startup biomedical company, Biorasis, and will soon be sent to the International Space Station for further study.

user or parent’s smartphone, or doctor’s office via cloud storage. The biosensor lasts from three months to a year, and has already earned the company recognition in the prestigious local technology competition “MassChallenge,” CASIS, and now, from M2D2.

vent a foreign body reaction that would otherwise prevent the flow of glucose in and out of the sensor, rendering it ineffective.

“People have obviously used glucose sensing before. It’s most commonly done through finger pricking and exterScaling Up While Sizing Down nally evaluating the blood sample. But the problem with that is that you only “My colleagues and I began working on receive the levels four to eight times this about 18 years ago, and my role has a day, and can’t tell whether glucose largely been in the development of the levels are going up or down.” The Glucoating material that allows the sensor cowizzard, however, monitors glucose to work in the body,” Burgess explained. levels 24/7, ensuring patients can’t miss “The coating we developed is a smart The company’s product, the “Glucowiz- coating, made of a hydrogel that allows a hyper- or hypoglycemic event. zard,” is an ultra-tiny wireless biosensor, glucose to penetrate through it easily.”

Burgess’ role as a pharmacist helped implanted under the skin to continuThe coating contains microspheres that drive the team toward some of the ously monitor glucose levels. Data is Glucowizzard’s most effective features. relayed in real time to a wristwatch-like slowly release the anti-inflammatory “Being a pharmacist and understanddrug dexamethasone that helps prereceiver that can project the signal to a ing patient compliance, I was adamant with my colleagues many years ago that we had to make this really, really tiny.”

The small size also served to confirm one of Burgess’ suspicions: the smaller the device, the lesser the inflammatory reaction. Professor of Electrical and Computer Engineering Faquir Jain’s work in the miniaturization of the device (which measures .5mm in diameter and 5mm long) allows it to be fully injected into the skin, unlike the semi-implantable, quarter-sized device Dr. Diane Burgess currently on the market. (left) received the 2014 AAPS Research Achievement Award in Formulation Design and Development and the 2014 AAPS Outstanding Educator Award.

The Gluccowizzard’s miniature size has another benefit: localized delivery.

“You could get the same effect by giving dexamethasone orally, but you’d have

Academic Pharmacy NOW  2016 Issue 2

9

community impact

Photo credit: Biorasis

to give a huge dose, and you’d get so many side effects,” Burgess said. “By releasing a very tiny amount locally, we’re getting just the amount we need without any of the side effects.”

The Sky’s Not Quite the Limit A needle implantable biosensor

The Magic of Teamwork Burgess collaborated with numerous colleagues within the University of Connecticut, including: •

Faquir Jain, School of Engineering

•

Fotios Papadimitrakopoulos, College of Liberal Arts and Sciences

•

Ilze Krisst, Biorasis

•

Michail Kastellorizios, Biorasis

Biorasis has received more than $3 million in federal grants through the years and has about $4.6 million in equity invested—much of it sweat equity by employees and in-kind exchanges by suppliers and others, Papadimitrakopoulos said. The state kicked in $150,000 to match a federal research grant.

Most recently, the company won a $250,000 grant from CASIS/Boeing to test its product on the International Space Station. Michail Kastellorizios, Director of R&D at Biorasis and Burgess’ former grad student, is heading

up research and development for the company. “Mike got a grant from CASIS/Boeing to test and optimize the biosensor auto-calibration algorithms in the International Space Station, where there’s no effect of gravity or other forces on the diffusion,” Burgess explained.

Human trials on the Glucowizzard are scheduled to begin early next year. The hope is to have a marketable product in three years, said Dr. IIze Krisst, the firm’s chief operating officer. The cash awards from Massachusetts and CASIS, she said, “are key to helping us transition from human testing to product development.” P Adapted from an article by Erik Hesselberg, Special to The Courant.

Additional reporting by Kyle Bagin, Communications Coordinator at AACP.

A Pathway to a Possible HIV Cure UNMC pharmacy dean part of international research team that looked at HIV drug delivery.

By Kalani Simpson, UNMC Public Relations An international team of scientists— among them Dr. Courtney Fletcher, dean of the University of Nebraska Medical Center College of Pharmacy— published a study in the journal Nature, which shows findings that suggest a pathway to a possible cure for HIV-1 infection.

The work builds upon a 2014 publication in the Proceedings of the National Academy of Sciences, of which Dr. Fletcher was first author, which investigated the question of why, despite being driven to undetectable levels in blood

10

Academic Pharmacy NOW  2016 Issue 2

by powerful antiretroviral drugs, HIV is never fully wiped out in patients with the disease.

In that study, Fletcher and colleagues found that a much lower concentration of the drugs made it to lymph node and lymphoid tissues, allowing viral replication—and persistence—of reservoirs of HIV in those tissues.

Finding out why low levels of HIV were hanging on, “for the first time allowed us to have a scientific-based conversation about a cure—is it possible?”

Fletcher said.

Special Delivery This latest study takes it a step further—and finds that while the levels of drug concentration that make it to those tissues are too low to wipe out HIV, the virus also has not developed a resistance to those drugs, as might usually be expected. In the current paper, the authors suggested this is likely because the levels of the drugs are so low, there was no reason for the virus to develop resistance.

“In simple terms, we think there is no evolutionary advantage to have devel-

community impact

oped a resistance,” Fletcher said.

And if it has no drug resistance, the scientists may have found a pathway to a possible cure.

tutes of Health, and he is optimistic that UNMC will be tasked with finding a way to deliver enough drugs to the hard-to-reach places where the last remaining bits of HIV hide out.

samples, and measured the amount of virus in the tissues; •

Northwestern University researchers explored the evolution of the HIV virus;

“Can we deliver more drug to these tissues and see if we can shut down replication?” Fletcher said. That’s the next problem to solve.

“We believe we are one of the few places • in the country—with some help from experts in virology around the country,” he emphasized—“to do this work.”

•

University of Oxford scientists took the lead on the mathematical side; and

“Will this cure HIV? No one knows,” Fletcher said. “But it is a very rational, evidence-based approach.

An International Collaboration

“This is a problem that we are extremely well positioned here at Nebraska to address. We think this problem of ongoing viral replication in lymphoid tissues may be solved by enhanced drug delivery, and that’s something that we here at UNMC are really good at.”

Already, Fletcher has a significant grant application in with the National Insti-

Fletcher stressed that it took an international partnership of top-notch academic medical centers, each bringing its own world-class expertise, to take on a project like this.

For example: •

Investigators at the University of Minnesota, with which Fletcher has long collaborated, recruited the patients into the original study, obtained the plasma and tissue

Researchers at the University of Edinburgh, in Scotland, brought to life the story of how the virus changes its genetic makeup.

Investigators at the Fred Hutchinson Cancer Research Center, in Seattle, the University of Porto, in Portugal, the University of California, San Diego, Korea National Institutes of Health, and King’s College London also made crucial contributions. P Kalani Simpson is a communications specialist at UNMC.

A previous study by Courtney Fletcher, Pharm.D., and colleagues determined there were lower concentrations of HIVfighting drugs in lymph node and lymphoid tissues, allowing the virus to replicate and remain in those tissues. This discovery, “for the first time allowed us to have a scientific-based conversation about a cure—is it possible?”

Academic Pharmacy NOW  2016 Issue 2

11

community impact

Not Blowing Smoke Academic pharmacy aims to reduce tobacco use to ashes.

Based on a report drafted by William Lang, Nervana Elkhadragy and Karen Suchanek Hudmon

Cigarette smoking kills more than 480,000 Americans each year, according to the Centers for Disease Control and Prevention, and smokingrelated illness costs the United States more than $300 billion a year. Tobacco use remains the single largest preventable cause of death, and in 2014, an estimated 16.8 percent of U.S. adults were current smokers1.

12

Academic Pharmacy NOW  2016 Issue 2

community impact

Tips from Former Smokers is a 20-week campaign, in multiple languages, and across all forms of media—particularly focusing on social media. AACP has so far contributed 17,434 impressions to the campaign, using the hashtag #CDCTips on our Facebook and Twitter pages. To access pharmacist-specific CDC resources, such as posters, videos, CE training courses and more, visit our social media pages or http://ow.ly/4mWAiX.

In early 2016, AACP became a partner with the CDC on its Tips from Former Smokers smoking cessation campaign.

Since the program’s launch in 2012, approximately 1.6 million people have tried to quit smoking, and approximately 100,000 have quit for good as a result. The 2016 campaign uses real-life examples of how smoking effects health, lives and families—and more importantly, provides resources for people who want to quit.

Given the negative consequences of tobacco use and the lack of adequate support at the state level for individuals interested in quitting, the CDC can benefit from a strong, more collaborative partnership with faculty, students, and graduates of U.S. colleges and schools of pharmacy to move our country toward the tobacco use goals of Healthy People 20202.

The geographic distribution of the current 135 accredited colleges and schools of pharmacy creates the opportunity for any number and type of patient population to be supported in its efforts to access evidence-based tobacco cessation resources. Access to these resources is provided by faculty, students and graduates whose competence is required and assessed through institutional accreditation standards and educational outcomes3,4 .

An Active Academy In February, AACP issued a survey to faculty at member institutions that was designed to assess and characterize their collective teaching, research and service provision activi-

1. http://www.cdc.gov/tobacco/campaign/tips/resources/data/ cigarette-smoking-in-united-states.html 2. USDHHS. Healthy People 2010. Washington, D.C.: U.S. Department of Health and Human Services; 2000.

ties related to tobacco cessation. In a letter signed by AACP Executive Vice President and CEO Lucinda L. Maine, survey participation was requested of all 135 accredited colleges and schools of pharmacy and underscored the value of the collected information toward strengthening the partnership between the CDC and AACP. The survey remained open for 16 days and a response was received from 94 schools (70 percent).

Below, the results of the survey are presented in three distinct sections describing how faculty at colleges and schools of pharmacy teach, conduct research and provide care or other service activities related to tobacco cessation.

Tobacco-related Teaching Survey items were constructed to provide detailed characterization of: •

the ways in which tobacco education and intervention skills are integrated into Pharm.D. curricula,

•

the number of hours of formal tobacco cessation instruction in required coursework,

•

the year(s) in which student pharmacists receive tobacco cessation training,

•

whether an interprofessional education (IPE) approach is utilized,

•

whether students learn about the tobacco quitline,

3. Accreditation Council for Pharmacy Education (ACPE). Accreditation Standards and key elements for the professional program in pharmacy leading to the Doctor of Pharmacy degree: Standards 2016. Available at: https://www.acpeaccredit.org/pdf/Standards2016FINAL.pdf Accessed April 20, 2016.

4. Medina MS, Plaza CM, Stowe CD, et al. Center for the Advancement of Pharmacy Education 2013 educational outcomes. Am J Pharm Educ. 2013;77(8):162.

Academic Pharmacy NOW  2016 Issue 2

13

community impact

•

methods of assessment used; and

•

to what extent schools utilize the Rx for Change: Clinician-Assisted Tobacco Cessation training program materials, a shared, comprehensive evidence-based curriculum that was developed by the schools of pharmacy in California and later and disseminated, with NIH funding, through train-the-trainer programs for faculty from schools of pharmacy between 2004 and 2006.

Survey results indicate that nearly all (98.9 percent) colleges/ schools integrate tobacco cessation content into required coursework (Table 1), providing a mean of 4.9 hours (standard deviation, 2.3 hours). These data suggest that 60 percent of schools are providing less than the minimum recommended six hours of training, and 11 percent are providing at or above the recommended eight hours of training (McBane et al., 2013). The year in which tobacco content was taught was variable, with 40 percent providing training in the first year of the Pharm.D. curriculum, 60 percent in the second year, 43 percent in the third year, 10 percent in the fourth year, and 2 percent in the fifth year (categories not mutually exclusive).

examination (32 percent), case-based short-answer examination (29 percent), objective structured clinical examination (OSCEs; 27 percent), and oral examinations (11 percent) (categories not mutually exclusive). Nearly three-fourths of schools/colleges utilize shared, evidence-based curricular materials from the Rx for Change program (Figure 1).

Because of the recent, rapid expansion of the total number colleges and schools of pharmacy in the U.S., efforts are underway to disseminate a 6-hour Web-based Rx for Change train-the-trainer program for pharmacy faculty who wish to teach tobacco cessation.

Tobacco-related Research Survey results suggest a wide range of tobacco-related research activities (Table 2), with nearly half of pharmacy schools being engaged in at least one type of research over the past five years. The most common type of research was the development/evaluation of evidence-based tobacco cessation interventions (n=18; 19 percent)

Service and Policy-related Tobacco Cessation Activities

In teaching tobacco cessation, 10 percent applied an interprofessional approach, and at 91 percent of schools/colleges, students learned about the tobacco quitline (1 800 QUIT NOW).

Among assessment methods, multiple-choice examination was most common (90 percent), followed by case-based multiple-choice examination (60 percent), short-answer

Survey results indicate that in the past three years, 11 schools/colleges (12 percent) implemented preceptor development activities related to tobacco cessation, and 46 (49 percent) partnered with a community-based organization to deliver tobacco cessation interventions. Specifically:

Table 1 Integration of tobacco cessation content into Pharm.D. coursework

Figure 1 Do instructors utilize the Rx for Change training materials when teaching students?

Course/activity

Number (%)a

Required course devoted only to tobacco education and intervention Part of a required course An elective course devoted only to tobacco education and intervention Part of an elective course IPPEb rotations that focus primarily on tobacco cessation APPEc rotations that focus primarily on tobacco cessation Community service or outreach (e.g., health fairs)

1 (1%)

Categories not mutually exclusive.

Introductory Pharmacy Practice Experiences c Advanced Pharmacy Practice Experiences a

b

14

Academic Pharmacy NOW  2016 Issue 2

93 (99%) 9 (10%) 20 (21%) 5 (5%) 6 (6%)

26.6% None

30.9% Most or all

42.6% Some

52 (55%) Portion of teaching materials that are from the Rx for Change program

community impact

•

47 (50 percent) provided one-on-one counseling to patients

•

21 (22 percent) participated in group programs for patients

•

36 (38 percent) participated in efforts to reduce smoking among vulnerable populations

in Figure 2 was provided as an example of a policy in an appendix to the survey, it is likely that other policies (e.g., tobacco-free campus policies) were included among those who responded positively to this survey question.

Exemplary Activities

The survey asked respondents to share what they deem to be exemplary teaching, research and service activities at • 38 (40 percent) integrated routine tobacco cessation their institution related to tobacco cessation. The breadth counseling in the treatment of patients with specific of the activities in these three categories indicates an entire chronic diseases (e.g., diabetes, cardiovascular disease, Academy committed to reducing the impact of tobacco use pulmonary disease, cancer) and preparing student pharmacists to be prepared to assist In 2014, faculty from the College of Pharmacy at Purdue Unitheir patients with quitting and their transitions toward a versity was the first to adopt a policy on reducing the health healthier lifestyle. burden associated with tobacco (Figure 2); since this time, the same policy has been adopted at 12 additional colleges/ Teaching schools of pharmacy and an initiative is currently underway Duquesne University by members of the Tobacco Subcommittee of the AACP In 2014, Duquesne was accredited through the Association Public Health Special Interest Group to advance its adoption for the Treatment of Tobacco Utilization and Dependence nationwide.

(ATTUD) as one of only 12 national providers of the “ToThe survey asked respondents, “Has your school adopted a Tobacco Policy on reducing the health burden associated with tobacco use?” Just under half (49 percent) responded “yes,” and of those who responded “no,” 62 percent indicated that they would like to learn more about this. It is important to note, however, that although the language presented

bacco Treatment Specialist” (TTS) certification program.

This 24-hour live training program certifies an interdisciplinary audience of healthcare professionals as Certified Tobacco Treatment Specialists (CTTS). These CTTS are well equipped with the knowledge and skills to assist patients with tobacco cessation.

Table 2 Tobacco-related research activities

Figure 2 Tobacco Policy Language

a

Reducing The Health Burden Associated With Tobacco Policy

Type of research

Number (%)a

None Evaluation of educational approaches for teaching tobacco cessation Development/evaluation of evidencebased tobacco prevention interventions Development/evaluation of evidencebased tobacco prevention interventions Development/testing of new drugs for tobacco cessation Testing of existing drugs targeted at tobacco cessation Evaluation of interventions (any type) related to tobacco cessation on patients’ health outcomes

49 (52%) 11 (12%)

WHEREAS, tobacco is the primary known cause of death in the U.S., contributing to the onset and exacerbation of numerous diseases, be it resolved that the faculty of the [PHARMACY SCHOOL OR COLLEGE NAME] shall:

7 (7%)

1.

Endorse policies, regulations, and legislation that aim to reduce the public health burden associated with tobacco.

18 (19%)

2.

Endorse widespread dissemination of evidence-based strategies to prevent the onset of tobacco use, increase tobacco cessation rates, and reduce exposure to second-hand smoke.

Categories not mutually exclusive.

7 (7%) 4 (4%) 11 (12%)

FURTHERMORE, because the sale of tobacco products is not consistent with the role of pharmacists as providers of health services or as advocates for public health, and because the sale of tobacco products are in direct violation of the pharmacist’s code of ethics, the School/College shall: 3.

Oppose the sale of and use of tobacco products in any facility or establishment where health care services are rendered.

4. Endorse policies to eliminate the sale of tobacco products in all pharmacies and stores that contain a pharmacy.

Academic Pharmacy NOW  2016 Issue 2

15

community impact

Web Exclusive To view the full report, Getting to Zero: The role of academic and professional pharmacy in tobacco cessation, including more exemplary programs utilizing smoking cessation activities, visit bit.ly/Getting2Zero.

Nova Southeastern University Nova Southeastern is working with its AHEC to implement required smoking cessation programs in the curricula of all Health Professions Division programs (e.g., medicine, nursing, pharmacy, PT, OT, optometry, dentistry, etc.). We are in the process of having the pharmacy faculty trained, which will be followed by curricular integration.

While the school currently has smoking cessation in the curriculum, this will be a more interprofessional approach including the College of Psychology.

Ohio Northern University The college of pharmacy has partnered with a local hospital to provide a 6-week multidisciplinary tobacco cessation class series that is open to anyone in the community.

Participants in this class will learn a positive approach to becoming a non-tobacco user, strategies to recover from tobacco addiction, the barriers to tobacco cessation, the health benefits of choosing a tobacco-free lifestyle, nicotine-replacement options, and motivational exercises and techniques for stress management.

Purdue University/University of California, San Francisco With funding from the NIH, faculty at Purdue University and UCSF are developing virtual patients and standardized patients for tobacco cessation counseling. These shared teaching tools will become broadly available to all health professional schools, for integration into formal coursework for health professional students. Additionally, UCSF and Purdue have collaborated on the maintenance of the shared Rx for Change tobacco cessation curricular resources since 1999.

Temple University Temple University School of Pharmacy and School of Dentistry have developed an interprofessional practice experience for PY3 pharmacy students and junior and senior dental students. Pharmacy and dental students work together to conduct health and medication histories for patients at the Diagnostic Radiology Clinic. While conducting these histories, dental and pharmacy students ask patients about their smoking status. If patients are current smokers, the students collaborate to conduct smoking cessation counseling. Dental students advise patients to quit and review the effects of smoking on oral health. Additionally, pharmacy students (1) reinforce the importance of quitting, (2) assess smoking history and past quit attempts, (3) assist

16

Academic Pharmacy NOW  2016 Issue 2

community impact

Web Exclusive Working Collaboratively Respondents, when answering questions related to their tobacco cessation service activities, shared the community-based organizations with whom they partner. To view the list, visit bit.ly/WorkingCollaboratively.

with quitting by recommending cognitive and behavioral strategies and pharmacotherapy when appropriate, and (4) refer interested patients to the Pennsylvania quitline.

The University of Texas at Austin Tobacco education and intervention skills by Dr. Kentya Ford: Exploratory Research Rotation Courses. Students conducted research targeting tobacco control, targeting smoking cessation approaches for the pharmacy profession and health disparities; developed manuscripts targeting evidenced-based approaches to smoking cessation, student pharmacist knowledge of tobacco products.

University of Florida The University of Florida College of Pharmacy participates in the University of Florida Area Health Education Centers (UF AHEC) Tobacco Training and Cessation—Initial Training (ATTAC-IT) program, which is an interprofessional activity involving all first-year health science center students (medicine, nursing, pharmacy, dental, public health and health professions students). This is a 4-hour workshop program where students work in small interprofessional teams (five to six students) in order to prepare them to work with tobacco users to deliver brief interventions to promote tobacco cessation. During the workshop, content focuses on introduction of motivational interviewing skills, engaging with a tobacco user utilizing roleplay activities to deliver brief interventions and practice motivational interviewing skills, and discussing the role of each profession in helping the tobacco user. This past year, we had 740 health science center students participate in this event. Since 2007, this program has trained approximately 6,000 health science center students.

Biomedical Research Creighton University The Creighton Cardiac Center has been spearheading efforts in investigating outcomes (both clinical and translational) after use of e-cigarettes.

Pacific University Oregon Dr. John Harrelson is conducting research in the evaluation of a natural product (cinnamic aldehyde from cinnamon) as a potential cessation agent, which may be an attractive option for tobacco-users who are unwilling or able to use current medications.

Academic Pharmacy NOW  2016 Issue 2

17

community impact

Western University of Health Sciences One area of focus in Dr. Fadi Khasawneh’s laboratory is to obtain evidence regarding the negative health consequences of exposure to a newly realized or discovered form of tobacco exposure known as third-hand smoke (THS) in the context of thrombotic disorders. THS is defined as the residual tobacco smoke contaminant that remains after a cigarette is extinguished. It is well established that both active/first-hand smoke (FHS) and passive/second-hand smoke (SHS) exposure increase the risk of coronary thrombosis. However, it remains to be determined whether THS can also enhance the risk of thrombogenesis, much like FHS and SHS. Therefore, his studies investigated the impact of THS exposure in the context of platelet biology and related disease states, using a validated mouse model of THS. He found that THS-exposed mice exhibited enhanced platelet activation responses (i.e., their platelets were hyperactive); that THS exposure shortens the tail bleeding time, as well as the occlusion time in a model of thrombosis. Thus, his data demonstrated for the first time (at least in mice) that THS exposure increases the risk of thrombosis-based disease states, which is attributed, at least in part, to their hyperactive platelets.

Health Services Research Harding University Harding is partnering with the Arkansas Health Department Tobacco Prevention and Cessation Service to learn how the state tobacco quitline has performed and what characteristics identify the patient who achieves a successful quit.

MCPHS University Evaluation of smoking cessation collaboration between a Community Health Worker and pharmacist in helping indigent patients quit smoking.

Purdue University/University of California, San Francisco With NIH funding, a team of faculty at Purdue and UCSF have collaborated in developing and implementing a 2-state, randomized trial evaluating the impact of 64 community pharmacies (pharmacists, technicians) in delivering brief interventions for tobacco cessation using the Ask-Advise-Refer (to the tobacco quitline) approach. This study demonstrated positive effects of the pharmacy team on incoming calls to the quitlines in Connecticut and Washington State. This model was later replicated within 20 Safeway Pharmacies in a randomized trial, and with funding from Pfizer, corporatewide Ask-Advise-Refer trainings were conducted and evaluated for Giant Eagle pharmacies.

18

Academic Pharmacy NOW  2016 Issue 2

University of Pittsburgh Research in past years has been completed evaluating the need/desire of smoking cessation in patients in underserved populations, specifically homeless and/or in Adult Rehabilitation Programs for patients with concomitant substance abuse disorders. This research was based on a belief that vulnerable patients in these populations are not interested in quitting tobacco. Research indicated quite the opposite— patients in these vulnerable populations are interested in tobacco cessation to a higher degree than the general population, however, barriers to therapy exist.

Service Campbell University Health coach: Pharm.D./D.O./P.A. students are trained as health coaches at the health center and participate in the tobacco cessation program “CU Quit Now” where the patient receives individualized counseling (in person or on the phone) at key days in the quitting process. Anyone who works on campus or attends CU is eligible to participate in the program free of charge.

Ohio Northern University In 2013, a community health assessment report identified priorities for healthcare in the county. Tobacco cessation was among the priorities identified to improve health. In light of information from this assessment, the college of pharmacy initiated a rural mobile health clinic to serve those who have limited or no access to health care services.

University of the Sciences USP has participated in the development and adoption of the tobacco cessation-related policies of the American Pharmacists Association and AACP, as well as advocacy through numerous editorials/commentaries in pharmacy publications for the discontinuation of the sale of tobacco products in pharmacies and stores that contain pharmacies, (i.e., letters and phone calls to the CEOs of chain pharmacies for the discontinuation of the sale of tobacco products in their pharmacies, meeting with the Pennsylvania State Board of Pharmacy to recommend adoption of a policy that would result in the Board not issuing or renewing licenses for pharmacies that sell tobacco products or to pharmacies that are in stores that sell tobacco products.) Additionally, USP has participated in advocacy through editorials and participation in Food and Drug Administration hearings for varenicline, nicotine nasal spray and nicotine inhalation system to be available without a prescription from a pharmacist.

community impact

Purdue University Through a state-funded grant, Purdue is working with the Department of Health to advance tobacco cessation activities and policies to reduce the health burden of tobacco use patients with mental illness. This includes providing technical support for promotion of tobacco-free facilities and grounds where mental health services are provided, as well as providing evidence-based cessation training for mental health providers. Additionally, in collaboration with UCSF, tobacco cessation training programs have been developed for broad-scale dissemination within the U.S. Public Health Service.

Temple University PY3 students spend 40 hours at Temple University Hospital counseling inpatients on smoking cessation and anticoagulation therapy during their PY3 IPPE experience. Students are oriented through lecture and then divided in groups of 8-10 students to complete role playing to practice patient counseling strategies for tobacco cessation. Students must also pass a competency exam before they may counsel inpatients. Pairs of students speak to inpatients and present the following information: risks of smoking and benefits of quitting, non-pharmacologic support and available pharmacologic therapy. Patients who are interested in the quitline are asked to sign a referral form, which is faxed so that the PA quitline calls them upon hospital discharge. Patients who are interested and appropriate for pharmacologic therapy receive counseling. Students also complete appropriate screening and contact medical residents to initiate or optimize pharmacologic agents.

University of California, San Francisco Working with the California Pharmacists Association, UCSF faculty are leading a training initiative for pharmacists who

Recognizing “Rx for Change” In recognition of their exceptional contributions and national impact in tobacco cessation education, Dr. Robin L. Corelli and Dr. Karen S. Hudmon were presented the U.S. Public Health Service’s Public Health Excellence Award by Assistant Surgeon General Rear Admiral Pamela Schweitzer at the APhA Federal Pharmacy Forum in March.

Corelli, professor in the Department of Clinical Pharmacy at the University of California, San Francisco’s School of Pharmacy, and Hudmon, professor of pharmacy practice at Purdue University College of Pharmacy, have regularly collaborated on tobacco since 1998, and with their “Rx for Change” tobacco cessation training program, drew the attention of the USPHS. The mission of the USPHS is to protect, promote and advance the health and safety in the United States, and the USPHS Public Health Excellence Award recognizes non-federal individuals who have made significant contributions to this purpose.

Corelli and Hudmon’s “Rx for Change” program equips health professions students and practicing clinicians of all disciplines with evidence-based knowledge and skills for assisting patients with quitting. The program has been tailored for several other health professions, including medical and dental assistants, pharmacy technicians and mental health professionals, and has even been adapted by the USPHS Commissioned Corps to train communities and health professionals. To access the program, free of charge, visit www.rxforchange.ucsf.edu.

From left: Karen S. Hudmon, Dr.P.H., M.S., Purdue University; Robin Corelli, Pharm.D., University of California, San Francisco; Rear Admiral Pamela Schweitzer, USPHS.

Academic Pharmacy NOW  2016 Issue 2

19

community impact

Want to learn more about the exemplary programs highlighted in the report?

Contact Will Lang at wlang@aacp.org.

wish to furnish prescription formulations of NRT, without a prescriber’s order, under new regulations set forth by Senate Bill 493. Additionally, for the past 10 years, faculty and student members of the Tobacco Awareness Project at UCSF have participated in the delivery of group tobacco cessation programs at the UCSF Fontana Tobacco Treatment Center.

All in This Together

2. CDC and AACP should discuss how community-based organizations with CDC connections can be encouraged to seek partnerships with colleges and schools of pharmacy so collaborative efforts might further CDC goals.

3. CDC and AACP should discuss strategies for increasing the role of team-based care in regard to tobacco cessation and other public health issues.

U.S. colleges and schools of pharmacy are actively engaged 4. CDC and AACP should discuss how the CDC can build in teaching, research, and service related to tobacco cessaand strengthen pharmacy faculty capacity to develop tion and control. To ensure that student pharmacists graduand test public health interventions including those that ate with contemporary knowledge to impact a wide-range keep individuals from starting to use tobacco products. of public health issues, including tobacco cessation, faculty regularly incorporate evidence-based interventions into their Through this survey, AACP reflects an actively engaged Acadcurricula. While much of the impetus for this public health emy committed to improving public health through teachfocus is related to accreditation standards and education ing, research and service. Faculty and students are partners outcomes, academic pharmacy recognizes the explicit trust with a wide array of community-based partners eager to that the public places in the pharmacist. This trust creates a improve the lives of their constituents. The CDC continues substantial opportunity for academic pharmacy to develop to recognize the benefit of pharmacists being integrated into new and strengthen existing partnerships with communityintervention implementation strategies aimed at improving based organizations engaged in efforts to reduce and eventu- population health. If our organizational priorities are the ally stop all forms of tobacco use. primary indication of our commitment, together the CDC and AACP can create a healthier United States. P Below are suggestions for strengthening the partnership between AACP and the CDC: William Lang, M.P.H., is Senior Policy Advisor at AACP. 1. CDC and AACP should discuss when is the best time for developing public health competencies in student pharmacists so community trust can be leveraged to address important public health issues.

20

Academic Pharmacy NOW  2016 Issue 2

Nervana Elkhadragy, Pharm.D., BCPS, is a Graduate Research Assistant at Purdue University College of Pharmacy.

Karen Suchanek Hudmon, Dr.P.H., M.S., R.Ph., is Professor of Pharmacy Practice at Purdue University College of Pharmacy.

@AACPharmacy

Connecting Our Knowledge Assets

By Dana Thimons, MLIS, M.S., AHIP Last year was one of the most exciting, challenging and educational years of my life. As the 2015 Sewell Memorial Fund Learning Partnership Fellow, I spent the year identifying AACP’s knowledge assets and working on a knowledge management (KM) framework and strategy. Members of the Academy shared their thoughts on KM with me via telephone and e-mail, as well as at various AACP meetings. Additionally, I visited several schools of pharmacy located near AACP headquarters and met with knowledge managers at other associations to learn how they are implementing KM. Fortunately, when the fellowship ended I was able to join AACP as the associate director of knowledge management.

The KM literature states that people, processes and technology are the three elements necessary for successful KM implementation. I am thrilled to continue working on these three elements to implement KM at AACP.

Technology A “hot topic” is AACP’s Web site. We all agree that it has the potential for improvement. AACP is currently working on a Web site revision with its projected completion in 2017. The new Web site will have better search functionality and be more user-friendly.

Many members expressed an interest in an online environment to collaborate with other individuals. I am currently working with a group of members who will test AACP Connect, our online platform that will facilitate sharing, searching and retrieving knowledge through discussion boards.

AACP Connect will also provide users with the ability to upload content, such as PDFs, Word documents and YouTube

videos. The pilot group will help to determine best practices, taxonomy and training needs. The beta test will begin in late May and run through August. Stay tuned for more information about AACP Connect!

AACP piloted several Twitter chats in 2015 as a way to exchange knowledge. The pilots were successful and there will be more Twitter chats in 2016.

People and Processes Another concept that emerged during my fellowship was to expand the role of the secretary in our governance groups to have more of a knowledge management focus. The intention is for this leadership position—called the Secretary of Knowledge Management—to serve as a KM champion within their governance group. In an effect to curtail the duplication of work, the Secretary of KM will help to gather and share the council, section or SIG’s knowledge assets. Vern Duba, who was recently elected as the Library and Information Science Section’s secretary, has graciously agreed to test this role. Vern will help to identify best practices and flesh out the duties of the Secretary of KM. If you are the secretary of your governance unit, do not worry. Everyone who was elected as a secretary will carry out his or her term as secretary.

There are many projects in the works to reduce silos and enable members to share content and expertise. Thank you for your assistance last year, and I look forward to your ideas and input moving forward! P Dana Thimons is the Associate Director of Knowledge Management at AACP.

Save the Date! September 26–28, 2016 2016 AACP Fall Institute:

Strengthening Holistic Review in Pharmacy Admissions Sheraton Charlotte Hotel, Charlotte, N.C. Academic Pharmacy NOW  2016 Issue 2

21

@AACPharmacy

change

innovation relationship-building patient-care management collaboration transformation

Innovation and Effective Leadership was the theme that guided the important conversations at this year’s Interim Meeting. But throughout the four days of learning and networking, one word resurfaced again and again: change.

By Maureen Thielemans Rapid change is taking place in healthcare and higher education and the leaders at our nation’s pharmacy schools are looking for innovative programs and effective models to address and flourish in this new and challenging environment. Tampa, Florida, was the perfect backdrop for discussions amongst deans, faculty and administrators on how to

“The changing landscape in healthcare includes a value-based clinical transformation of aligning people, processes and technologies to improve outcomes. When it comes to healthcare, the patient’s bottom line is this: it must be easy and affordable for me to be well and stay well.”

—Edmund F. Funai, M.D., Chief Operating Officer and Vice President for Administration, University of South Florida Health “When physicians graduate from medical school, they enter a practice. When student pharmacists graduate, they take jobs. We must fix this.”

—Daniel E. Buffington, Pharm.D., MBA, President and Practice Director, Clinical Pharmacology Services, Inc.

enhance student recruitment, develop relationships with academic partners, and accelerate change within practice and education, just to name a few.

Following are some of the highlights of the meeting, held Feb. 21–23, as told through the collective wisdom shared from some of the meeting’s esteemed speakers.

“We need innovative approaches to recruitment and effective strategies to implement them. We must think about what we’re already doing—and determine what’s working. How do we get to the flag? We must promote the profession of pharmacy and create a powerful brand.”

—Jennifer Adams, Pharm.D., Ed.D., and Stephanie Fouch, AACP Judy Genshaft, CEO of the University of South Florida System and President of the University of South Florida, knows about changing the culture of a university.

She once asked a USF student for the shirt off his back and replaced it with one donning the University of South Florida colors and logo.

“Followers want leaders who can be trans“Stop the problem solving and replace with solution finding. Change is an ongo- parent, be with them when the going gets ing discovery process; how do I get there tough, and reduce ambiguity while raising with less stress and effort? The best lead- hope. Great leaders add positivity (not ers are the ones who can access answers happiness) into the culture.”

—Nance Lucas, Ph.D., Executive Director, from the best people.”

Center for the Advancement of Well-Being —Doug Krug, CEO, e.l. Solutions

22

Academic Pharmacy NOW  2016 Issue 2

“One size does not fit all when it comes to leadership. Do we say mentoring when we mean coaching? Delegation should include guidance, trust and accountability. We empower but we don’t always educate.”

—Evan Robinson, R.Ph., Ph.D., Dean, Western New England University College of Pharmacy

Dr. Evan Robinson calls on meeting attendees to examine the development of the next generation of leaders within the Academy.

@AACPharmacy

NMA

Real-Time Results

The 2016 Interim Meeting marked the return of the Nonprescription Medicines Academy (NMA) Faculty Development Program. NMA began in 1997 with the mission to support pharmacy faculty by providing important and impactful information, as well as faculty development programming, on nonprescription medicines and self-care conditions.

#AACPInterim created a sense of community during which attendees networked with each other face-to-face but also on social media. They used Twitter, Facebook and Instagram to share thoughts, opinions, questions and best practices on-the-spot. Relive some of the social media enthusiasm from the meeting by checking out these tweets:

For two days prior to the Interim Meeting, a record number of self-care faculty from the nation’s schools and colleges of pharmacy met for the acquisition of self-care knowledge and teaching skills, to share teaching innovations and strategy, and to promote scholarship in the areas of self-care and nonprescription medications.

@chrisleemph: #Pharmacy is not a commodity. #Pharmacists are not pill-counting robots @Ron_Jordan @AACPharmacy @RxDeanMac @drobrx @DZgarrick #AACPinterim @_gbrazeau: Thanks for reminding us to stop problem solving. Replace it with Solution Finding!-Doug Krug #unepharmacy #AACPInterim #AACPharmacy @imagine1957: #AACPInterim Focusing on the future is the key according to Doug Krug—the power of gap analysis— stating our future and finding a way @profhogue: A map is good; a compass is good; a map and a compass is better. #developingleaders #evanrobinson #AACPInterim @NHilliard: “Management is doing things right; Leadership is doing the right things”. #AACPInterim @CynthiaJBoyle: Whether leaders are born or made, our ALFP Fellows are future leaders! #AACPInterim @AACPharmacy

In the Academic Leadership Fellows Program debates, Fellows argued both sides to critical issues such as navigating resistance to change, whether leadership is innate or learned, and the differences between leading and managing.

@RxDeanMac: [What] if you could go to university and try a program for a couple of weeks to see if it is “for me”? @lcpugliese #AACPInterim @jlaadams

Exciting Events Ahead

@LynetteBBaker: Three factors that lead to better performance and satisfaction: Autonomy, Mastery, and Purpose. #AACPInterim

Engaging with fellow Interim Meeting attendees post-conference is easy thanks to the Web Event App. Visit https:// interim16.pathable.com/ and log-in to review speaker materials.

@DavidDAllen: #AACPInterim “Culture eats strategy for breakfast” More great leadership insights from Nance Lucas. @olemisspharmacy

Looking for more in-person learning opportunities? Registration is now open for the premier pharmacy education event, the AACP Annual Meeting, July 23–27 in Anaheim, Calif. Leaders will again meet for the 2017 Interim Meeting, Feb. 25–28, in Puerto Rico. P

Maureen Thielemans is Associate Director of Communications at AACP and editor of Academic Pharmacy Now.

Academic Pharmacy NOW  2016 Issue 2

23

Registration is Now Open

AACP Annual Meeting/July 23–27, 2016

Anaheim Marriott / Anaheim Convention Center / Anaheim, California

colleagues and hear from experts in / Join education, science and technology—and

discover new opportunities for pharmacy and pharmacy education.

www.aacp.org/PharmEd16

On Twitter? Follow us! Tweet @AACPharmacy with #PharmEd16